Concure Oncology
Concure Oncology develops the Breast Microseed Treatment, a brachytherapy procedure that implants radioactive seeds after tumor removal to treat early-stage breast cancer.
Facts
- HQ
- Mercer Island
- Sectors
- Healthcare, Medical Devices, Oncology, Medical Technology
- Stage
- Seed
- Members see funding amounts. .
Is this your organization? Claim it
Concure Oncology raises $2.5M from ~25 investors to expand Breast Microseed radioactive-seed therapy
Concure Oncology raised $2.5 million from nearly 25 investors to expand adoption of its Breast Microseed Treatment, a brachytherapy that implants rice-grain-sized radioactive palladium seeds after tumor removal to kill remaining cancer cells. The Mercer Island startup has now secured over $12 million total and will use the round to double its field sales team and train clinicians nationwide.
Concure Oncology raises $3 million to advance Breast Microseed radioactive-seed treatment for early-stage breast cancer
Concure Oncology raised $3 million in a new SEC filing to fund its Breast Microseed brachytherapy treatment, which uses tiny radioactive titanium seeds to kill remaining cancer cells after tumor removal and prevent recurrence in early-stage breast cancer patients.
Concure Oncology raises $5M from insiders to bring Canadian Breast Microseed therapy to U.S.; available at Swedish Cancer Institute
Concure Oncology raised $5 million from insiders to introduce its Canadian-developed Breast Microseed treatment to the U.S., using implanted radioactive palladium-titanium seeds to deliver targeted post-surgery radiation and reduce breast cancer relapse.